



Aclaris Therapeutics to Attend Upcoming Investor Conferences

May 10, 2018

WAYNE, Pa., May 10, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that management will attend the following conferences:

- Management will host investor meetings during the Bank of America Merrill Lynch's 2018 Healthcare Conference in Las Vegas, NV on Wednesday, May 16, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare Conference in New York, NY on Tuesday, June 5, 2018 at 1:30 PM EST. Management will also host investor meetings on Tuesday, June 5, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL on Wednesday, June 13, 2018 at 11:20 AM CT. Management will also host investor meetings on Wednesday, June 13, 2018.
- Management will participate on panels and host investor meetings during the 2018 Cantor Dermatology & Aesthetics Summit in New York, NY on Tuesday, June 19, 2018.
- Management will participate on a panel and host investor meetings during the 2018 JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 20, 2018.

A live webcast of the Jefferies 2018 Healthcare Conference presentation and the William Blair 38th Annual Growth Stock Conference presentation may be accessed through the Company's web site, www.aclaristx.com, on the 'Events and Presentations' section. An archived version of the presentation will be available for 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Contact:

Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy / Investor Relations
484-329-2140
mtung@aclartistx.com



Source: Aclaris Therapeutics, Inc.